Physician profile
Mridula Sood
NPI 1699854117
$597.33
in general payments reported to CMS, 2019-2025
14 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $153 · 2023: $26.71 · 2024: $167 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $444.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $95.46 | 2024-2025 | Ams 700, Lux-Dx Insertable Cardiac Monitor |
| Janssen Biotech, INC. | $87.99 | 2022-2024 | Stelara |
| Pfizer INC. | $81.13 | 2024-2025 | |
| Exact Sciences Corporation | $58.02 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $53.54 | 2022-2025 | |
| Lilly USA, LLC | $32.86 | 2024 | Omvoh |
| Biogen, INC. | $27.90 | 2025 | Spinraza |
| Novo Nordisk INC | $26.57 | 2025 | Wegovy |
| Alexion Pharmaceuticals, INC. | $25.09 | 2022 | |
| Agios Pharmaceuticals, INC. | $24.98 | 2022 | |
| Watermark Medical, INC. | $22.70 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.89 | 2025 | Jardiance |
| Taiho Oncology, INC. | $20.69 | 2022 | |
| Profound Medical Corp. | $18.51 | 2025 | Tulsa-Pro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mridula Sood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.